Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention

Toru Ishikawa

doi:10.5114/ceh.2025.155228

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Send email

Copy url:

abstract:

Review paper

Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention

Toru Ishikawa

¹

Saiseikai Niigata Hospital, Japan

Clin Exp HEPATOL 2025; 11, 4

DOI: https://doi.org/10.5114/ceh.2025.155228

Online publish date: 2025/10/21

View full text Get citation

PlumX metrics:

The link between lifestyle-related conditions and fatty liver disease has attracted considerable attention in recent years. The number of patients with metabolic dysfunction-associated steatotic liver disease (MASLD), often co-occurring with obesity, diabetes, and dyslipidemia, continues to rise. Accumulating evidence suggests that these conditions synergistically increase the risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Consequently, there is a growing need for testing to identify high-risk liver disease patients based on lifestylerelated conditions, distinct from chronic viral hepatitis or alcohol-induced liver disease, and to determine the most appropriate treatments for these conditions, especially obesity, diabetes, and dyslipidemia. This review outlines the strategy for treating fatty liver disease currently being used in community hospitals, with the goal of reducing HCC and preventing cardiovascular disease.

keywords:

metabolic dysfunction-associated steatotic liver disease, hepatocellular carcinoma, hepatic function reserve, non-alcoholic fatty liver disease, cardiovascular disease

Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention

Toru Ishikawa 1

metabolic dysfunction-associated steatotic liver disease, hepatocellular carcinoma, hepatic function reserve, non-alcoholic fatty liver disease, cardiovascular disease

Toru Ishikawa

¹